Thanks Nigel, as most suspected, the linkage continues. Curagen does not list investment backers on their releases, except for a small time 15m placement. But << J.P. Morgan & Co. is acting as lead manager for the offering. Goldman, Sachs & Co., Merrill Lynch & Co., Warburg Dillon Read LLC, Lehman Brothers, Inc., and Robertson Stephens are co-managers.>> from th Genentech site, and from Tularik << Tularik Inc. Files Registration Statement For Initial Public Offering Of Common Stock
South San Francisco, Calif. October 15, 1999 -- Tularik Inc. announced today that it
has filed a registration statement with the Securities and Exchange Commission for a
proposed initial public offering of 6,250,000 shares of common stock. The offering is
being made through an underwriter group managed by Lehman Brothers Inc.,
Hambrecht & Quist LLC, J.P. Morgan & Co. and Warburg Dillon Read LLC. >>
Not only does this have a little "conflict of interest oder" but is this not a hint of extorsion - use us or it will go worse for you?
Would an SEC complaint have any slight chance of making a difference?
Not that I need more stuff to do.
Back to some serious, non-investment analysis. Scott |
